Literature DB >> 9590488

A step in the right direction: assessing exercise tolerance in cystic fibrosis.

I M Balfour-Lynn1, S A Prasad, A Laverty, B F Whitehead, R Dinwiddie.   

Abstract

Exercise tolerance may be reduced in patients with cystic fibrosis, but it is not always possible to predict this from standard lung function measurements. Formal exercise testing may, therefore, be necessary, and the test should be simple and readily available. We have developed a "3-minute step test" and compared it with the standard 6-minute walking test. Subjects stepped up and down a 15-cm-high single step at a rate of 30 steps per minute for 3 minutes. The effect of the step test on spirometry was tested first in 31 children with CF (mean age, 12.0 years), who had a mean (range) baseline forced expired volume in 1 second (FEV1) of 64% (18-94%) of predicted values. The step test was then compared with the standard 6-minute walk in a further 54 patients with cystic fibrosis (mean age, 12.5 years), with mean (range) baseline FEV1 of 61% (14-103%) of predicted values. Outcome measures were minimum arterial oxygen saturation (SaO2), maximum pulse rate, and the modified Borg dyspnea score. Post-step test spirometry showed mean (95% CI) changes of -1.1% (-6.0 + 3.9%) for forced vital capacity, of -1.6% (-4.2 + 1.1%) for FEV1, and +0.25% (-2.8 + 3.3%) for peak expiratory flow, although 5/31 children showed >15% drop in one or more parameters. The step and walk tests both produced significant changes (P < 0.0001) in all outcomes, with a mean (range) minimum SaO2 of 92% (75-98%) versus 92% (75-97%), a maximum pulse rate of 145 b.p.m. (116-189) versus 132 (100-161), and a Borg score of 2.5 (0-9) versus 1.0 (0-5), respectively. Comparison of the two tests showed that the step test increased breathlessness (mean change Borg score, 2.3 vs. 0.8; P < 0.0001) and pulse rate (mean change, 38% vs. 24%, P < 0.0001) significantly more than the walk, whereas the decrease in SaO2 was similar (mean change, -2.9% vs. -2.6%; P = 0.12). Some patients with a significant drop in SaO2 (>4%) would not have the decrease predicted from their baseline lung function. Reproducibility for the two tests was similar. The step test is quick, simple and portable, and is not dependent on patient motivation. Although the step test is more tiring, its effect on SaO2 is similar to the 6-minute walking test. It is a safe test that may prove to be a valuable measure of exercise tolerance in children with pulmonary disease, although longitudinal studies are now needed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590488     DOI: 10.1002/(sici)1099-0496(199804)25:4<278::aid-ppul8>3.0.co;2-g

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  13 in total

Review 1.  Physiotherapy in cystic fibrosis.

Authors:  S A Prasad; E L Tannenbaum; C Mikelsons
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

2.  Exercise testing in children with cystic fibrosis.

Authors:  Diane Rogers; S Ammani Prasad; Iolo Doull
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

3.  Exercise testing in cystic fibrosis: why (and how)?

Authors:  D S Urquhart
Journal:  J R Soc Med       Date:  2011-07       Impact factor: 5.344

4.  Rating of Perceived Exertion in Three-Minute Step Test in Children with Cystic Fibrosis.

Authors:  Amanda P Silva; Erika V Araujo; Igor P Machado; Livia F Alves; Marcos F DA Silva Mello; Pedro Henrique DE A Silva; Isabella R Dias; Viviane Soares
Journal:  Int J Exerc Sci       Date:  2021-04-01

5.  Six-Minute Walk Test Vs. Three-Minute Step Test for Measuring Functional Endurance.

Authors:  Richard W Bohannon; Deborah J Bubela; Ying-Chih Wang; Susan S Magasi; Richard C Gershon
Journal:  J Strength Cond Res       Date:  2015-11       Impact factor: 3.775

6.  Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study.

Authors:  L Borgwardt; C I Dali; J Fogh; J E Månsson; K J Olsen; H C Beck; K G Nielsen; L H Nielsen; S O E Olsen; H M F Riise Stensland; O Nilssen; F Wibrand; A M Thuesen; T Pearl; U Haugsted; P Saftig; J Blanz; S A Jones; A Tylki-Szymanska; N Guffon-Fouiloux; M Beck; A M Lund
Journal:  J Inherit Metab Dis       Date:  2013-03-14       Impact factor: 4.982

Review 7.  New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.

Authors:  Michael Beck
Journal:  Hum Genet       Date:  2006-11-07       Impact factor: 5.881

Review 8.  Oxygen therapy for cystic fibrosis.

Authors:  R Dinwiddie; S Madge; S A Prasad; I M Balfour-Lynn
Journal:  J R Soc Med       Date:  1999       Impact factor: 18.000

9.  The feasibility and validity of a remote pulse oximetry system for pulmonary rehabilitation: a pilot study.

Authors:  Jonathan Tang; Allison Mandrusiak; Trevor Russell
Journal:  Int J Telemed Appl       Date:  2012-09-24

10.  Natural history of alpha mannosidosis a longitudinal study.

Authors:  Michael Beck; Klaus J Olsen; James E Wraith; Jiri Zeman; Jean-Claude Michalski; Paul Saftig; Jens Fogh; Dag Malm
Journal:  Orphanet J Rare Dis       Date:  2013-06-20       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.